

14th August, 2024

The Dy. General Manager (Listing Dept.) **BSE Limited** Corporate Relationship Dept., 1st Floor, New Trading Ring, P. J. Towers, Dalal Street, Fort, Mumbai - 400 001

(BSE Scrip Code: 500420)

Dear Sir,

The Manager – Listing Dept., National Stock Exchange of India Ltd., Exchange Plaza, 5th Floor, Plot No. C/1, G. Block, Bandra - Kurla Complex, Bandra (E), Mumbai – 400 051

(NSE Scrip Code: TORNTPHARM)

Sub.: Clarification / Information on news item

This is with reference to e-mail received from BSE on 13th August, 2024 and the letter received from NSE, bearing reference no. NSE/CM/Surveillance/14603 dated 13th August, 2024, seeking clarification/ confirmation in respect of the news item appeared on the "Websitewww.economictimes.com" captioned - "Torrent Pharma is said to seek raising \$3 billion for KKR s stake in JB Chemicals" on 13th August, 2024.

In this regard, we would like to clarify as follows:

- In terms of Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) 1. Regulations, 2015 ("Listing Regulations"), the Company has promptly intimated the stock exchanges regarding all events and disclosed all information, that have a bearing on the operations / performance of the Company which include all price sensitive information, etc., as and when required.
- 2. At this stage, there is no material event/ information that requires disclosure under Regulation 30 of the Listing Regulations. If and when any proposal warranting a disclosure is considered by the board of directors of the Company, the Company shall promptly comply with the disclosure obligations under Regulation 30 of the Listing Regulations.
- 3. Considering that the shares of the Company are freely traded on the stock exchanges, we note that there has been no material price movement, and accordingly, the Company does not have any further comments.

Thanking you,

Yours Sincerely,

For TORRENT PHARMACEUTICALS LIMITED

CHINTAN M. TRIVEDI **COMPANY SECRETARY**

TORRENT PHARMACEUTICALS LIMITED